Piper Sandler Initiates Coverage On RxSight with Neutral Rating, Announces Price Target of $18
RXSTApril 15, 2025
Read more →UBS Downgrades RxSight to Neutral, Lowers Price Target to $16
RXSTApril 9, 2025
Read more →Needham Maintains Buy on RxSight, Lowers Price Target to $22
RXSTApril 9, 2025
Read more →Wells Fargo Maintains Equal-Weight on RxSight, Lowers Price Target to $17
RXSTApril 7, 2025
Read more →Deep Dive Into RxSight Stock: Analyst Perspectives (12 Ratings)
RXSTApril 4, 2025
Read more →JP Morgan Downgrades RxSight to Underweight, Lowers Price Target to $17
RXSTApril 4, 2025
Read more →RxSight Analyst Flags Growth Slowdown As Revised Outlook Misses Expectations
RXSTRxSight revised its FY25 revenue outlook below estimates, with Q1 sales lagging expectations. BofA downgraded the stock, citing slowing growth and risks ahead.
April 3, 2025
Read more →Wells Fargo Maintains Equal-Weight on RxSight, Lowers Price Target to $22
RXSTApril 3, 2025
Read more →Needham Reiterates Buy on RxSight, Maintains $43 Price Target
RXSTApril 3, 2025
Read more →RxSight Warns On FY25 Revenue As Premium Cataract Market Faces Headwinds, Stock Plunges
RXSTRxSight shares down premarket on revised FY25 outlook. CEO cites headwinds in premium IOL market and economy.
April 3, 2025
Read more →Reported Earlier, RxSight Preliminary Q1 Results: Expects Revenue of $37.9M, Up 28% YoY (Vs. $40.14M Est.); Lowers 2025 Revenue Guidance To $160M–$175M (Vs. $188.9M Est.), Down From $185M–$197M
RXSTApril 3, 2025
Read more →B of A Securities Maintains Buy on RxSight, Lowers Price Target to $36
RXSTMarch 21, 2025
Read more →The Analyst Verdict: RxSight In The Eyes Of 9 Experts
RXSTMarch 19, 2025
Read more →Expert Outlook: RxSight Through The Eyes Of 11 Analysts
RXSTFebruary 26, 2025
Read more →JP Morgan Maintains Overweight on RxSight, Lowers Price Target to $40
RXSTFebruary 26, 2025
Read more →Stifel Maintains Hold on RxSight, Lowers Price Target to $33
RXSTFebruary 26, 2025
Read more →Wells Fargo Maintains Equal-Weight on RxSight, Lowers Price Target to $35
RXSTFebruary 26, 2025
Read more →Needham Reiterates Buy on RxSight, Maintains $43 Price Target
RXSTFebruary 26, 2025
Read more →RxSight Affirms FY2025 Sales Guidance of $185.00M-$197.00M vs $188.50M Est
RXSTFebruary 25, 2025
Read more →RxSight Q4 2024 Adj. EPS $0.03 Up From $(0.13) YoY, Sales $40.214M Miss $40.318M Estimate
RXSTFebruary 25, 2025
Read more →Wells Fargo Maintains Equal-Weight on RxSight, Lowers Price Target to $40
RXSTJanuary 13, 2025
Read more →Stifel Maintains Hold on RxSight, Lowers Price Target to $35
RXSTJanuary 13, 2025
Read more →Needham Reiterates Buy on RxSight, Maintains $66 Price Target
RXSTJanuary 13, 2025
Read more →Needham Reiterates Buy on RxSight, Announces $66 Price Target
RXSTJanuary 13, 2025
Read more →RxSight Sees Q4 Revenue $40.2M Vs. $40.4M Est; Sees FY 2024 Revenue ~$139.9M,Up 57% YoY
RXSTJanuary 12, 2025
Read more →Forecasting The Future: 4 Analyst Projections For RxSight
RXSTDecember 20, 2024
Read more →Stifel Downgrades RxSight to Hold, Lowers Price Target to $40
RXSTDecember 20, 2024
Read more →